A Phase 2 interventional study of Oxaliplatin, capecitabine and Oxaliplatin, capecitabine in Rectal Neoplasms, sponsored by Sanofi. Completed at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-04.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies testing oxaliplatin in Rectal Neoplasms — 14 open to participants now, 22 under way, 6 of them phase 3. Oxaliplatin · Rectal Neoplasms.
Among the 152 studies testing oxaliplatin in Rectal Neoplasms, this one is the 41st largest by enrollment of the 131 interventional ones that give a count, is one of 12 that started in 2006, is one of 76 in phase 2, and was the 77th registered.
2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.
Browse Rectal Neoplasms studies →14 of the 152 studies testing oxaliplatin in Rectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
First Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 18–75
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–75
Canadian Cancer Trials Group · Sites in United States, Canada
Ages 18+
Sir Run Run Shaw Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →
Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 95 · Phase 3 34 · Phase 4 1
First in 1998; this study’s year is marked. 12 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 65 across 1,753 interventional studies indexed under Rectal Neoplasms.
Median enrollment 58 across the 131 interventional studies. Of the 96 that completed or were terminated, 18 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 152 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
10 studies in Rectal Neoplasms by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 8 finished, 2 (25%) have results posted.
Among the 10 studies in Rectal Neoplasms by Sanofi, this one is the only one that started in 2006, is one of 5 in phase 2, and was the 7th registered.
Sanofi’s Rectal Neoplasms studies by the year they started, since 2000.
2 of the studies testing oxaliplatin in Rectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02008656Memorial Sloan Kettering Cancer CenterTrial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management | 2026-11 |
| NCT05000697Hospital Alemão Oswaldo CruzChemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 152 studies testing oxaliplatin in Rectal Neoplasms, from their registry updates:
Among Sanofi’s 10 in Rectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary:
Secondary:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Oxaliplatin, capecitabine
Drug: Oxaliplatin, capecitabine
Drug pages: Oxaliplatin · Capecitabine
OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
Also known as: Radiotherapy
Drug pages: Oxaliplatin · Capecitabine
XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
Also known as: Radiotherapy
Response rate
Time frame: from the signature of Informed Consent up to the end of the study
Relative dose intensity
Time frame: from the signature of Informed Consent up to end of the study
Disease free survival
Time frame: from the signature of Informed Consent up to end of the study
Overall survival
Time frame: from the signature of Informed Consent up to end of the study
The record gives a start of May 2006, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxaliplatin · Capecitabine